Archived Clinical Trials

Gynecology

  • Sequenom SQNM-T21-304 - A Clinical Study to Evaluate the Clinical Performance of the SEQureDx® Trisomy 21 Test in the Detection of the Relative Quantity of Chromosome 21 in Circulating Cell-Free DNA Extracted from a Maternal Blood Sample Obtained from Pregnant Women with One or More High Risk Indicators for Fetal Chromosome 21 Aneuploidy

Oncology

  • Amgen 20080259 - A Phase 3, Randomized, Double-blind, Placebo-controlled Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab and Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI) (Closed to Enrollment)

  • Bayer 73-4506_14387 - A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (Closed to Enrollment)

  • Bayer BAY 73-4506 17347 - Does physician education influence side effect management and does it increase time on treatment in the absence of progression? A phase 4 open-label trial with regorafenib in metastatic colorectal cancer

  • CALGB 40502 - A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer (Closed to Enrollment, Effective November 30, 2011)

  • CALGB 40503 - Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab for Women with Hormone Receptor-Positive Advanced Breast Cancer (Closed to Enrollment, Effective November 30, 2011)

  • CALGB 70604 - A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (Closed to Enrollment, Effective April 13, 2012)

  • CALGB 80702 - A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer

  • CALGB 90401 - A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab (IND #7921, NSC #704865) In Men with Hormone Refractory Prostate Cancer (Closed to Accrual, Effective 12/21/07)

  • CINJ 130901 - Health Behaviors among Individuals Diagnosed with Colorectal Cancer

  • CINJ 131025 - Decisional Aid Intervention For Women Considering Breast Reconstruction

  • ECOG 1504 - Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features (Closed to Accrual Effective December 12, 2008)

  • ECOG 1505 - A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) (Closed to Enrollment, Effective September 20, 2013)

  • ECOG 1602 - A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T cells and Helper T cells for Patients with Metastatic Melanoma (Closed to Accrual, Effective January 12, 2009)

  • ECOG 1A05 - Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®)-Lenalidomide (Revlimid®)-Dexamethasone (VRD) versus Bortezomib (Velcade®)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen (Closed to Enrollment, Effective May 7, 2010)

  • ECOG 2108 - A Randomized, Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer (Closed to Enrollment, Effective July 23, 2015)

  • ECOG 2204 - An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely Resected Pancreatic Carcinoma (Closed to Accrual, Effective 1/9/08)

  • ECOG 2603 - A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma (closed to accrual April 22, 2008)

  • ECOG 2805 ASSURE - A Randomized, Double Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (Closed to Enrollment, Effective September 1, 2010)

  • ECOG 2905 - A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- Or Intermediate-1 Risk MDS and Symptomatic Anemia

  • ECOG 2Z04 - Quality of Life in Younger Breast Cancer Survivors (Closed to Accrual, Effective December 23, 2008)

  • ECOG 4112 - Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS) (Closed to Enrollment, Effective April 20, 2016)

  • ECOG 4A03 - A Randomized Phase III Study of CC-5013 plus Dexamethasone versus CC-5013 plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage Therapy for Non-Responders (Closed to Accrual, Effective June 1, 2007)

  • ECOG 5103 - A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (Step 1 Closed to Enrollment, Effective February 28, 2011)

  • ECOG 5202 - A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (Closed to Enrollment, Effective February 11, 2011)

  • ECOG 5204 - Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation (Closed to Accrual, Effective April 29, 2009)

  • ECOG 5508 - Randomized Phase III Study of Maintenance Therapy of Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC (Closed to Enrollment)

  • ECOG JMA17 - A Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen (Closed to Accrual on May 8, 2009)

  • ECOG PACCT-1 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial (Closed to Registration, Effective October 6, 2010)

  • ECOG SWOG 9346 - Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III (Closed to Accrual Effective September 1, 2008)

  • ECOG-ACRIN E1Z11 - A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Note: Only the Asian cohort is presently open to enrollment.

  • Fox Chase 94-016 - Genetic Research Studies in Sporadic, Familial and Hereditary Forms of Cancer

  • Fox Chase FER-GU-004 - Phase II Trial of Cetuximab With and Without Weekly Paclitaxel in Patients with Previously Treated Advanced Urothelial Cancer

  • Gilead GS-US-370-1296 - A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase

  • GOG 0209 - Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer (Closed to Accrual)

  • GOG 0218 - A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC#704865, IND #7921) Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III (Suboptimal) and All Stage IV, Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Cancer (Temporarily Closed to Accrual)

  • GOG 0258 - A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed By Carboplatin and Paclitaxel Vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (Closed to Enrollment, Effective July 28, 2014)

  • ImClone IMCL CP12-0917 - An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients with Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

  • Millennium C16014 - A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

  • NCCTG N0147 - A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer (Permanently Closed to Accrual)

  • NCCTG N0723 - A Phase III Biomarker Validation Study of Second-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib (Closed to Accrual)

  • NCCTG N107C - A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS)Compared with Whole Brain Radiation Therapy (WBRT) for Resected Metastatic Brain Disease

  • NewLink Genetics NLG-0505 - A Phase III Study of FOLFIRINOX With or Without Algenpantucel-L (HyperAcute®- Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

  • Novartis CBKM120F2302 - A Phase III Randomized, Double Blind Placebo Controlled Study of Oral BKM120 in Combination With Fulvestrant, in the Treatment of Postmenopausal Women With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Whose Disease Has Progressed on or After Aromatase Inhibitor Treatment

  • Novartis CICL670A2421 - An Open-Label, Phase II, Randomized, Pilot Study To Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone In Patients With Low- and Int-1-Risk Myelodysplastic Syndrome

  • Novartis CLBH589DUS94X - An Expanded Treatment Protocol of Panobinostat (LBH589) In Combination With Bortezomib and Dexamethasone In Patients With Multiple Myeloma Who Have Had At Least One Prior Line of Therapy (Closed to Enrollment)

  • Novartis CMEK162B2301 - A Phase III Randomized, 3-Arm, Open Label, Multicenter Study Of LGX818 Plus MEK162 and LGX818 Monotherapy Compared with Vemurafenib in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

  • NSABP B-39 RTOG 0413 - Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer (Closed to Enrollment, Effective, Apirl 16, 2013)

  • NSABP B-42 - A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer (Closed to Enrollment)

  • NSABP B-43 - A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

  • NSABP B-47 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer (Closed to Enrollment, February 10, 2015)

  • NSABP B-49 - A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (Closed to Enrollment)

  • NSABP P-5 - Statin Polyp Prevention Trial in Patients with Resected Colon Cancer (Closed to Enrollment, Effective September 10, 2013)

  • NSABP R-04 - A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-FU with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum (Closed to Enrollment, Effective August 16, 2010)

  • PrECOG PrE0501 - A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination with Docetaxel and Carboplatin ± Placebo or Maintenance Therapy with Vandetanib in Patients with IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

  • RTOG 0212 - A Phase II/III Randomized Trial of Two Doses (Phase III- Standard vs. High) and Two High Dose Schedules (Phase II-Once vs. Twice Daily) For Delivering Prophylactic Cranial Irradiation for Patients with Limited Disease Small Cell Lung Cancer (Closed to Accrual, Effective February 12, 2008)

  • RTOG 0320 - A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone versus with Temozolomide or Erlotinib in Patients with Non-Small Cell Lung Cancer and 1-3 Brain Metastases

  • RTOG 0522 - A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas (Closed to Accrual)

  • RTOG 0614 - Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy (Closed to Accrual, Effective December 17, 2008)

  • RTOG 0815 - A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer

  • RTOG 0825 - Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma (Closed to Enrollment)

  • RTOG 0839 - Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed By Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-small Cell Lung Cancer (Approved for 3D Only)

  • RTOG 0937 - A Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-cranial Erradiation for Extensive Disease Small Cell Lung Cancer (Approved for 3D and IMRT)

  • RTOG 1005 - A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionaton Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer (Closed to Enrollment)

  • RTOG 1012 - Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer (Approved for 3D and IMRT)

  • RTOG 1021 - A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotatic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Lung Cancer(NSCLC)

  • RTOG 1203 - Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer

  • RTOG 1205 - Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

  • Seattle Genetics SGN35-017 - A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment RCHOP or RCHP As Front-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

  • SWOG S0325 - A Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) In Chronic Phase (Closed to Accrual Effective February 28, 2009)

  • SWOG S0600 - Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab With or Without Bevacizumab As Second-Line Therapy for Patients With Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX (Closed to Enrollment, Effective November 10, 2010)

  • SWOG S1207 - Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year Of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and Her2/Neu Negative Breast Cancer

  • UNC LCCC 1029 - A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Therapy in Patients with Metastatic Colorectal Cancer

  • Wyeth 3144A2-3003-WW - A Phase 3, Randomized, Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2-Positive Locally Advanced or Metastatic Breast Cancer

Surgery

  • Torax 4959 - A Randomized Controlled Trial of LINX versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease